Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo NVXSWX:COPN -7.69%78 EV-to-EBIT is -258.92 as of Jul. 25, 2026. GuruFocus rates XSWX:COPN with a GF Score™ of 78/100 and a GF Value™ of CHF40.71 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 690 Drug Manufacturers companies, Cosmo NV ranks worse than 144927.39% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cosmo NV's Enterprise Value is CHF922.55 Mil.
Cosmo NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-3.56 Mil. Therefore, Cosmo NV's EV-to-EBIT for today is -258.92.
The historical rank and industry rank for Cosmo NV's EV-to-EBIT or its related term are showing as below:
XSWX:COPN'
s EV-to-EBIT Range Over the Past 10 Years
Min: -2415.4 Med: 13.07 Max: 659.78
Current: -258.92
During the past 13 years, the highest EV-to-EBIT of Cosmo NV was 659.78. The lowest was -2415.40. And the median was 13.07.
XSWX:COPN's EV-to-EBIT is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 15.46
vs XSWX:COPN: -258.92
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cosmo NV's Enterprise Value for the quarter that ended in Jun. 2026 was CHF974.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-3.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV EV-to-EBIT Related Terms
Cosmo NV EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cosmo NV's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:COPN vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Cosmo NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo NV EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cosmo NV's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cosmo NV's EV-to-EBIT falls into.
Cosmo NV's current Enterprise Value is CHF922.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo NV's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF-3.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo NV (XSWX:COPN) has a EV-to-EBIT of -258.92 as of Jul. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosmo NV and its competitors. According to the industry distribution chart, Cosmo NV ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Cosmo NV's EV-to-EBIT too high?
Cosmo NV's current EV-to-EBIT is -258.92. Based on the distribution chart, Cosmo NV ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cosmo NV has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosmo NV's EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Cosmo NV ranks #999999 out of 690 companies for EV-to-EBIT. This places Cosmo NV in the lower half of its industry. The industry median EV-to-EBIT is 15.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.46, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosmo NV and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo NV's current EV-to-EBIT is -258.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo NV stock overvalued right now?
Based on GuruFocus' analysis, Cosmo NV (XSWX:COPN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF40.71, compared to a current price of CHF63.60 — trading 56.2% above its estimated fair value. The current EV-to-EBIT is -258.92. Cosmo NV's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cosmo NV (XSWX:COPN), the current EV-to-EBIT is -258.92 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo NV (XSWX:COPN) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo NV stock appears to be overvalued.
The current stock price of CHF63.60 is trading 56.2% above its estimated GF Value™ of CHF40.71.
GuruFocus considers Cosmo NV to be Significantly Overvalued.
Key valuation signals for XSWX:COPN:
EV-to-EBIT: -258.92
GF Value™: CHF40.71 vs. price of CHF63.60 (56.2% above fair value)
No single metric tells the full story. See the XSWX:COPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo NV is is a life sciences company. The company is focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs, develops, and manufactures solutions to address critical medical needs. Its technologies are trusted by international pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. The product pipeline includes Eleview, GI Genius, Winlevi, Lialda, Uceris, and others.
78GF Score
Get the complete analysis for XSWX:COPN
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:COPN has been successfully added to your 
